After more than four months of fighting the new coronavirus, the world has collected a wealth of data on the pathogen, which has been used to improve treatments and develop new treatments that could reduce the virus’s lethality or even eradicate it. While developing a vaccine is still a priority, other drugs can speed up recovery and prevent life-threatening complications, and Ridsiewe may be one of them.
The drug was produced for Ebola and later used to treat SARS-CoV-2. A large U.S. study shows that Redciewe can significantly speed up recovery, but it does not reduce mortality. Describing Ridsiewe’s potential, Dr. Anthony Fauci, a top Infectious Disease expert in the United States, said future research will need to combine the drug with other drugs to achieve better results. Now some researchers believe they have found a way to reduce the risk of death from severe COVID-19 cases, which involves the use of more common drugs.
A growing body of reporting and research has shown an unusual condition in patients with COVID-19: blood clots. Blood clots in veins or arteries, clogging blood vessels. This can lead to neurological symptoms, including stroke in young patients. They can clog blood vessels in the heart, which can lead to heart attacks. Blood clots may even interfere with gas exchange between blood and lung cells.
Around the same time, reports said some doctors were considering using blood thinners on some COVID-19 patients. Researchers recently wrote a study that explained new blood clotting symptoms that may occur in patients with COVID-19. They call it pulmonary intravascular coagulation (PIC).
“In addition to pneumonia, which affects small air bags in the lungs, we also found hundreds of small blood clots throughout the lungs. This condition is not visible in other types of lung infections, which explains why blood oxygen levels drop sharply during infection in severe COVID-19 cases. Professor James O’Donnell, director of the RCSI Vascular Biology Centre in Ireland, said at the time. “Further research is needed to investigate whether different blood-thinning treatments play a role in selected high-risk patients to reduce the risk of thrombosis. “
Researchers from Italy, who carried out autopsies on COVID-19 deaths, said blood clot problems may be more important than initially thought and may be the cause of respiratory problems. A new study from Mount Sinai Health System in New York says the use of blood thinners for patients with COVID-19 symptoms can be very helpful in reducing mortality in patients who already have respiratory complications and need to use a ventilator. The study, published in the Journal of the American College of Cardiology in the form of a pre-trial draft, needs further validation. Still, the results are impressive.
The researchers looked at more than 2,700 patients hospitalized for COVID-19 and found that the proportion of patients who died without a ventilator, whether or not they had received blood-thinning drugs, was about the same. But patients who used blood-thinning (anticoagulant) drugs survived a week longer than those who did not receive the drug. In other words, people who received blood thinners survived 21 days, while others had 14 days.
In addition, seriously ill patients who use ventilators and receive anticoagulant drugs in intensive care units are more likely to survive. Sixty-three percent of those who received the drug survived, compared with 29 percent of those who did not. These patients were randomly assigned to blood-thinning therapy, but the study noted that other explanations for why those patients were better could not be ruled out. Anticoagulants increase dysplored risk in some patients, but studies have found no significant risk in those who receive treatment.
More research is needed to determine how blood-thinning drugs should be applied to patients with COVID-19, the researchers said. Doctors at Mount Sinai Hospital, who had given blood thinners to some patients before the results were released, changed their approach, according to the new findings. “Once we get these results, we have a new policy,” said study co-author Valentin Fuster, a lead physician at Mount Sinai Hospital. “That is to increase the dose of anticoagulant drugs in patients with COVID-19. “
Some patients may need to use anticoagulants to reduce the risk of blood clotting due to pre-existing diseases. These patients were treated with blood thinners upon admission. But in the intensive care unit, a higher dose was given. Mount Sinai Hospital will conduct a second observational study, which will look at 5,000 patients with COVID-19 who receive blood thinners. A randomized clinical trial will follow. Mount Sinai neurosurgeon J. Mocco detailed the increase in stroke in young patients, and another treatment that may work in some patients is anticoagulant drugs.
If all goes well, and future studies have shown that blood-thinning drugs can reduce blood clotting and prevent COVID-19 complications that can lead to death, we may see anticoagulant drugs become one of the standard treatments for the disease.